舒尼替尼治疗伴有3级高胆红素血症的肾癌脉膜转移完全消退。

IF 1.8 4区医学 Q3 ONCOLOGY

Anti-Cancer Drugs Pub Date : 2025-04-18 DOI:10.1097/CAD.0000000000001720

Wala Ben Kridis, Raafat Ben Lassoued, Amira Trigui, Afef Khanfir

{"title":"舒尼替尼治疗伴有3级高胆红素血症的肾癌脉膜转移完全消退。","authors":"Wala Ben Kridis, Raafat Ben Lassoued, Amira Trigui, Afef Khanfir","doi":"10.1097/CAD.0000000000001720","DOIUrl":null,"url":null,"abstract":"Sunitinib is a small molecule tyrosine kinase inhibitor that is taken by mouth. It works against several kinases, such as vascular endothelial growth factor receptor, c-Kit, and platelet-derived growth factor receptor. We report a case of total disappearance of choroid metastases from renal cell carcinoma after 6 months of sunitinib, with grade 3 hyperbilirubinemia.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complete regression of choroidal metastases from renal cancer under sunitinib with grade 3 hyperbilirubinemia.\",\"authors\":\"Wala Ben Kridis, Raafat Ben Lassoued, Amira Trigui, Afef Khanfir\",\"doi\":\"10.1097/CAD.0000000000001720\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sunitinib is a small molecule tyrosine kinase inhibitor that is taken by mouth. It works against several kinases, such as vascular endothelial growth factor receptor, c-Kit, and platelet-derived growth factor receptor. We report a case of total disappearance of choroid metastases from renal cell carcinoma after 6 months of sunitinib, with grade 3 hyperbilirubinemia.\",\"PeriodicalId\":7969,\"journal\":{\"name\":\"Anti-Cancer Drugs\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-Cancer Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/CAD.0000000000001720\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Cancer Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CAD.0000000000001720","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

舒尼替尼是一种小分子酪氨酸激酶抑制剂，口服。它对几种激酶起作用，如血管内皮生长因子受体、c-Kit和血小板衍生生长因子受体。我们报告一例在使用舒尼替尼6个月后肾细胞癌脉膜转移完全消失的病例，伴有3级高胆红素血症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Complete regression of choroidal metastases from renal cancer under sunitinib with grade 3 hyperbilirubinemia.

Sunitinib is a small molecule tyrosine kinase inhibitor that is taken by mouth. It works against several kinases, such as vascular endothelial growth factor receptor, c-Kit, and platelet-derived growth factor receptor. We report a case of total disappearance of choroid metastases from renal cell carcinoma after 6 months of sunitinib, with grade 3 hyperbilirubinemia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anti-Cancer Drugs 医学-药学

CiteScore

3.80

自引率

0.00%

发文量

244

审稿时长

3 months

期刊介绍： Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.